Dashboard
Manage Tickers

CMMB Chemomab Therapeutics Ltd.

Nasdaq chemomab.com


$ 2.43 $ -0.27 (-10 %)    

Thursday, 20-Nov-2025 15:46:24 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 586.20 $ -14.20 (-2.37 %)
DIA $ 458.32 $ -3.66 (-0.79 %)
SPY $ 653.07 $ -10.10 (-1.52 %)
TLT $ 89.25 $ 0.35 (0.39 %)
GLD $ 374.67 $ -0.11 (-0.03 %)
$ 2.43
$ 2.70
$ 2.43 x 1,094
$ 2.47 x 100
$ 2.43 - $ 2.70
$ 2.39 - $ 9.84
187,651
na
50.91M
$ 1.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-11-2023 03-31-2023 10-Q
2 03-20-2023 12-31-2022 10-K
3 11-10-2022 09-30-2022 10-Q
4 08-12-2022 06-30-2022 10-Q
5 05-12-2022 03-31-2022 10-Q
6 03-30-2022 12-31-2021 10-K
7 11-12-2021 09-30-2021 10-Q
8 08-13-2021 06-30-2021 10-Q
9 05-13-2021 03-31-2021 10-Q
10 03-09-2021 12-31-2020 10-K
11 11-16-2020 09-30-2020 10-Q
12 08-14-2020 06-30-2020 10-Q
13 05-07-2020 03-31-2020 10-Q
14 03-17-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

chemomab-therapeutics-q3-eps-028-beats-040-estimate
Chemomab Therapeutics Q3 EPS $(0.28) Beats...
11/20/2025 13:30:31

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of...

chemomab-to-present-abstracts-highlighting-new-clinical-data-from-nebokitug-phase-2-spring-trial-in-primary-sclerosing-cholangitis-at-aasld-2025
Chemomab To Present Abstracts Highlighting...
11/06/2025 13:09:30

— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patien...

oppenheimer-maintains-outperform-on-chemomab-therapeutics-raises-price-target-to-25
Oppenheimer Maintains Outperform on Chemom...
08/27/2025 16:22:29

Oppenheimer analyst Jeff Jones maintains Chemomab Therapeutics (NASDAQ:CMMB) with a Outperform and raises the price target f...

trading-halt-halted-at-75000-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 7:50:00 p.m. ET - ...
08/25/2025 23:50:05

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
08/19/2025 21:06:03

correction-chemomab-therapeutics-q2-epads-009-misses-007-estimate
CORRECTION: Chemomab Therapeutics Q2 EPADS...
08/14/2025 14:01:55

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate ...

chemomab-achieves-fda-alignment-on-cmc-and-non-clinical-toxicology-regulatory-path-for-nebokitug-in-psc
Chemomab Achieves FDA alignment On CMC And...
06/11/2025 12:15:06

chemomab-therapeutics-lead-product-nebokitug-awarded-new-patent-protections-in-china-and-russia
Chemomab Therapeutics' Lead Product Neboki...
06/03/2025 12:09:25

—New Patents Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclerosing Cholangitis Issued in C...

oppenheimer-maintains-outperform-on-chemomab-therapeutics-lowers-price-target-to-10
Oppenheimer Maintains Outperform on Chemom...
05/16/2025 17:34:22

Oppenheimer analyst Jeff Jones maintains Chemomab Therapeutics (NASDAQ:CMMB) with a Outperform and lowers the price target f...

update-chemomab-therapeutics-q1-epads-014-misses-010-estimate
UPDATE: Chemomab Therapeutics Q1 EPADS $(0...
05/15/2025 13:26:28

chemomab-announces-presentation-of-nebokitug-phase-2-clinical-data-in-primary-sclerosing-cholangitis-in-distinguished-plenary-session-at-ddw-2025
Chemomab Announces Presentation Of Nebokit...
05/05/2025 12:09:50

SPRING Trial Data Presented at Digestive Disease Week® 2025 Shows that Nebokitug at 15 and 48 Weeks of Treatment Is Well-Tolera...

chemomab-reports-data-from-two-study-abstracts-to-be-presented-at-annual-congress-of-the-european-association-for-the-study-of-the-liver-may-7-10
Chemomab Reports Data From Two Study abstr...
04/28/2025 12:02:45

New Analyses of PSC Data from Phase 2 SPRING Trial Show that Treatment with Nebokitug Is Associated with Dose-Dependent and Sig...

chemomab-therapeutics-touts-positive-data-from-experimental-drug-for-chronic-liver-disease
Chemomab Therapeutics' Touts Positive Data...
03/27/2025 19:18:23

Chemomab's OLE study of nebokitug in PSC patients confirmed safety and showed improvements in liver stiffness, fibrosis bio...

chemomab-announces-results-from-open-label-extension-portion-of-phase-2-spring-trial-says-over-90-of-spring-trial-patients-eligible-to-participate-in-ole-chose-to-continue
Chemomab Announces Results From Open Label...
03/27/2025 12:40:48

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
03/25/2025 21:05:55

chemomab-therapeutics-presents-new-data-highlighting-clinical-potential-of-its-nebokitug-in-systemic-sclerosis-at-cora-2025-conference
Chemomab Therapeutics Presents New Data Hi...
03/06/2025 13:48:07

Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic Sclerosis TEL...

chemomab-therapeutics-q4-eps-0008-vs-0013-yoy
Chemomab Therapeutics Q4 EPS $(0.008) vs $...
03/03/2025 13:10:32

maxim-group-maintains-buy-on-chemomab-therapeutics-raises-price-target-to-7
Maxim Group Maintains Buy on Chemomab Ther...
02/20/2025 18:26:19

Maxim Group analyst Michael Okunewitch maintains Chemomab Therapeutics (NASDAQ:CMMB) with a Buy and raises the price target ...

Core News & Articles
Market-Moving News for February 19th
02/19/2025 12:23:29

CMMB: 41% | Chemomab Therapeutics shares are trading higher after the company announced the completion of its end-of-phase 2 FD...

chemomab-therapeutics-shares-are-trading-higher-after-the-company-announced-the-completion-of-its-end-of-phase-2-fda-meeting-and-alignment-on-a-single-phase-3-registration-study-for-nebokitug
Chemomab Therapeutics shares are trading h...
02/19/2025 12:17:10

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION